NASDAQ:CLSDClearside Biomedical Stock Price, Forecast & News

Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLSD shares have decreased by 37.1% and is now trading at $1.63.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Clearside Biomedical.

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Clearside Biomedical.

Clearside Biomedical Inc (NASDAQ:CLSD) issued its quarterly earnings data on Monday, August, 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.13). Clearside Biomedical had a negative return on equity of 165.19% and a negative net margin of 293.61%.
View Clearside Biomedical's earnings history.

5 equities research analysts have issued 1-year price objectives for Clearside Biomedical's stock. Their forecasts range from $4.00 to $8.00. On average, they expect Clearside Biomedical's share price to reach $5.75 in the next twelve months. This suggests a possible upside of 252.8% from the stock's current price.
View analysts' price targets for Clearside Biomedical.

Media headlines about CLSD stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Clearside Biomedical earned a coverage optimism score of -2.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
View the latest news about Clearside Biomedical.

Clearside Biomedical saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 2,670,000 shares, an increase of 11.3% from the January 31st total of 2,400,000 shares. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is presently 2.1 days. Currently, 8.1% of the company's shares are sold short.
View Clearside Biomedical's Short Interest.

Some companies that are related to Clearside Biomedical include Aeglea Bio Therapeutics (AGLE), MEI Pharma (MEIP), Immunic (IMUX), Concert Pharmaceuticals (CNCE), OptiNose (OPTN), Arbutus Biopharma (ABUS), Tiziana Life Sciences (TLSA), Avadel Pharmaceuticals (AVDL), Affimed (AFMD), Osmotica Pharmaceuticals (OSMT), Bicycle Therapeutics (BCYC), ProQR Therapeutics (PRQR), Selecta Biosciences (SELB), Spero Therapeutics (SPRO) and Menlo Therapeutics (MNLO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), OrganiGram (OGI), Zosano Pharma (ZSAN) and Gran Tierra Energy (GTE).

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Clearside Biomedical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Principal Financial Group Inc. (0.08%), Johnson Investment Counsel Inc. (0.04%), First Citizens Bank & Trust Co. (0.03%) and Virtu Financial LLC (0.03%). Company insiders that own Clearside Biomedical stock include Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay and Nancy J Hutson.
View institutional ownership trends for Clearside Biomedical.

CLSD stock was acquired by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Johnson Investment Counsel Inc., First Citizens Bank & Trust Co., and Virtu Financial LLC. Company insiders that have bought Clearside Biomedical stock in the last two years include Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, and Nancy J Hutson.
View insider buying and selling activity for Clearside Biomedical.

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLSD stock can currently be purchased for approximately $1.63.

Clearside Biomedical has a market capitalization of $75.54 million and generates $2.17 million in revenue each year. The company earns $-30,770,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe.

The official website for Clearside Biomedical is www.clearsidebio.com.

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]